Corticosteroids in Duchenne Muscular Dystrophy: Deflazacort versus Prednisone
A newly diagnosed 5-year-old boy, still ambulatory, about to start standard corticosteroid therapy. The disagreement is which drug — and how much the family's own cost constraint should weigh against a modest functional advantage.
The mother of A.R., a 5-year-old boy, keeps a running list on her phone of the small things that used to be effortless and now visibly cost him — standing up from the living room floor by walking his hands up his own legs, a maneuver she didn't know had a name until his geneticist called it Gower's sign and confirmed, with genetic testing, what his rising creatine kinase had already suggested: Duchenne muscular dystrophy. She still remembers the pediatrician who first noticed his calves looked unusually full for a toddler, a finding she'd assumed was just healthy chubbiness at the time. A.R. is still fully ambulatory, still keeping up with his kindergarten class most days, and his growth is tracking normally at the 40th percentile for height. His mother has already read enough to know that starting a corticosteroid now, before real decline sets in, is the guideline-recommended standard — and that the specific drug matters as much as the decision to start one at all.
FOR-DMD — Guglieri and colleagues, 2022 — the randomized double-blind trial that directly compared daily deflazacort, daily prednisone, and intermittent prednisone in corticosteroid-naive boys like A.R., found deflazacort produced significantly less weight gain over the trial period, with functional outcomes comparable to or modestly favoring deflazacort on some measures — but also a higher rate of cataracts and more pronounced growth suppression than prednisone. For a five-year-old with decades of expected growth ahead of him, that tradeoff isn't abstract. A.R.'s family is a single-income household, and deflazacort's real cost premium over generic prednisone is, his mother says plainly, a number she needs to know before agreeing to anything.
Weight gain against growth suppression, with cost in the room
I'd recommend deflazacort. FOR-DMD, Guglieri and colleagues in 2022, is the actual randomized head-to-head trial here — 196 corticosteroid-naive boys, daily deflazacort against daily prednisone against intermittent prednisone — and it found significantly less weight gain with deflazacort than with daily prednisone, with the two daily regimens outperforming the intermittent one on function — and current DMD care guidelines list it as a reasonable preferred first option for exactly that reason. For a boy this young, avoiding excess weight gain matters for both mobility and self-image over the years he'll be on this regimen.
The weight-gain advantage is real, and I want to be clear I'm not disputing FOR-DMD's finding. But that same trial also found more growth suppression and a higher cataract rate with deflazacort than with prednisone — and A.R. is five, with most of his expected growth still ahead of him. Prednisone's weight-gain profile is manageable with dietary counseling in a way that lost height, once it happens, isn't reversible.
There's also the family's stated cost concern, which isn't a secondary consideration here — deflazacort's real price premium over generic prednisone is exactly the kind of access barrier that determines whether a family can sustain a therapy for years, not just start it.
There's a dosing-strategy question that sits somewhat apart from which specific drug we choose. An intermittent, high-dose weekend regimen — described in the DMD literature as a way to preserve benefit while reducing cumulative side-effect exposure — is worth discussing with the family regardless of whether we land on deflazacort or prednisone.
Given their stated cost concern, I'd lean toward prednisone on an intermittent schedule as the starting plan, with an honest conversation that we can revisit deflazacort later if weight gain becomes a real functional problem rather than a hypothetical one.
Agreed: intermittent prednisone started on a weekend schedule, with baseline DEXA and ophthalmologic exams arranged. The family was given clear cost figures for both agents before deciding.
Not agreed: whether deflazacort's functional and weight-gain advantages should have taken priority over cost and growth-suppression concerns in a different family's circumstances — left explicitly as a case-specific decision, not a general preference for one agent.